Skin Changes From the Use of Moisturizers in Participants With Cancer Experiencing Dermatological Adverse Events

NCT07767448 | Not Yet Recruiting

• 2 other identifiers: IRB-86852NCI-2026-06569
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to evaluate whether cosmeceutical topical moisturizers can help with skin dryness in participants with cancer experiencing a dermatological adverse event from cancer therapies. The main question it aims to answer is: Does cosmeceutical topical moisturizers help with skin dryness? Participants will:

• Visit the clinic for a baseline visit to complete skin evaluation and tests.
• Apply cosmeceutical topical moisturizers daily from baseline up until the follow-up visit.
• Visit the clinic for a follow-up visit (approximately 2-4 weeks from baseline) for a repeat skin evaluation and tests.

Conditions

Cancer

Outcome Measures

Primary Outcomes (1)

• Change in Patient-Reported Skin Dryness Severity

  Change in patient-reported skin dryness severity from baseline to follow-up visit (2-4 weeks) as measured by validated dryness severity scale (0-10 numerical rating scale where 0 = no dryness and 10 = severe dryness).

  From baseline visit to follow-up visit (approximately 2-4 weeks).

Secondary Outcomes (3)

• Time to improvement in dryness symptoms

  From baseline visit to follow-up visit (2-4 weeks).

• Change in Stratum Corneum Hydration

  From baseline visit to follow-up visit (2-4 weeks).

• Change in Transepidermal Water Loss (TEWL)

  From baseline visit to follow-up visit (2-4 weeks).

Study Arms (1)

Moisturizer

EXPERIMENTAL

Participants in this arm will apply the following cosmeceutical topical moisturizers twice daily (once in the morning and once in the evening) for the duration of the study: 1. La Roche Posay Lipikar wash Atopy-Prone Plus (AP+) moisturizing face and body wash (once in the morning and once in the evening) 2. La Roche Posay Lipikar AP+ triple repair moisturizing cream (once in the morning and once in the evening) 3. La Roche Posay Cicaplast balm Panthenol/Vitamin B5 (B5+) (once in the morning and once in the evening)

Other: La Roche Posay Lipikar Wash Atopy-Prone Plus (AP+) Moisturizing Face and Body Wash; Other: La Roche Posay Lipikar AP+ Triple Repair Moisturizing Cream; Other: La Roche Posay Cicaplast balm Panthenol/Vitamin B5 (B5+)

Interventions

La Roche Posay Lipikar Wash Atopy-Prone Plus (AP+) Moisturizing Face and Body Wash OTHER

Moisturizer wash applied once in the morning and once in the evening.

Moisturizer

La Roche Posay Lipikar AP+ Triple Repair Moisturizing Cream OTHER

Moisturizer applied once in the morning and once in the evening.

Moisturizer

La Roche Posay Cicaplast balm Panthenol/Vitamin B5 (B5+) OTHER

Balm applied once in the morning and once in the evening.

Moisturizer

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adult patient (18 years or older).
• Patients diagnosed with cancer.
• Patient receiving cancer treatment or therapy (receiving chemotherapy, targeted treatment, hormonal therapy, and/or immune checkpoint inhibitors).
• Patient experiencing a dermatological adverse event from a cancer treatment or therapy.

You may not qualify if:

• Patient is unable to understand scope of the study.
• Patient is unable to provide written informed consent.
• Patient is healthy.

Sponsors & Collaborators

• Stanford University: lead
• L'Oreal: collaborator

Study Sites (1)

Stanford Health Care: Supportive Dermato-Oncology Program

Palo Alto, California, 94304, United States

Location

MeSH Terms

Conditions

Neoplasms

Interventions

Pantothenic Acid

Intervention Hierarchy (Ancestors)

Imides; Organic Chemicals; beta-Alanine; Alanine; Amino Acids; Amino Acids, Peptides, and Proteins

Study Officials

• Lisa Zaba, MD, PhD

  Stanford University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Clinical Research Coordinator

CONTACT

650-497-1218; hannah05@stanford.edu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 10, 2026
• First Posted: August 17, 2026
• Study Start: October 1, 2026
• Primary Completion (Estimated): September 1, 2028
• Study Completion (Estimated): February 1, 2029
• Last Updated: September 11, 2026

Record last verified: 2026-09

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)